1. HBW Insight
  2. >>Health
  3. >>Policy & Regulation
  4. >>Regulation

No Change To US FDA’s Risk-Based Homeopathic Enforcement From Its OTC Monograph Overhaul

 
• By Malcolm Spicer

Final guidance presents same descriptions of six "categories of homeopathic drug products ... potentially posing higher risks to public health” agency stated in 2019 revised draft. Agency adds reference to monograph reform in explanation of how homeopathics aren't GRASE.  

FDA final guidance presents same descriptions of six areas of enforcement priorities – “certain categories of homeopathic drug products marketed without the required FDA approval as potentially posing higher risks to public health” – agency stated in a 2019 revised draft guidance. • Source: Shutterstock

Adding a statement that an overhaul of its OTC drug monograph program didn’t affect the US Food and Drug Administration’s oversight of homeopathic drugs is the biggest change between the agency’s draft and final guidances on regulating the Rx and OTC products.

The guidance the FDA published on 7 November presents the same descriptions of six areas of enforcement priorities –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Opella: Unlock Volume Growth By Expanding Access And Deepening Category Penetration

 
• By David Ridley

Negative growth in global OTC market sales volume means that “as an industry, we're not doing good enough,” argues Opella’s Asia Pacific, Middle East and Africa (AMEA) head, Carol-Ann Stewart, in this exclusive feature interview.

Like Claims Of Prenatal Acetaminophen Exposure Risks, Petition For Warning Is ‘Unreliable’ – CHPA

 
• By Malcolm Spicer

Scientific literature on potential link between prenatal acetaminophen exposure and neurological conditions “now includes FDA’s most recent epidemiological review” completed in May saying research results “insufficient to support a causal association.”

Norway Decides Against Tighter Restrictions For Ibuprofen

 
• By Tom Gallen

Norway's Medical Products Agency has rejected claims that misuse of OTC ibuprofen is linked to its availability for purchase in outlets other than pharmacies.

Latest OTC Eye Drop Production Problem In US Prompts Firm To Close Doors After Recalls

 
• By Malcolm Spicer

BRS Analytical Services in St. Louis recalled more than 75,000 cases of redness and lubricating eye drops and committed “to permanently cease production of all drugs.”

More from Policy & Regulation

Stopgap Spending Bill Provides Platform To Plug Gaps In FDA’s OTC Monograph, Switch Pathways

 
• By Malcolm Spicer

OMUFA reauthorization and directions for FDA to provide reports on monograph program and guidance on improving chances for OTC switch applications included in recent stopgap spending bill to end federal government shutdown.

Bayer: Product Launches Alone ‘Not Enough’ To Meet Women’s Health Needs

 
• By David Ridley

“It’s not good enough just to provide products anymore, we need to create a service and a holistic approach to products,” argued Bayer Consumer Health's Northern Europe general manager, Mike Knowland, speaking at a recent panel event in the UK Parliament.

BMJ Study: No Clear Link Between In Utero Paracetamol Exposure And Autism, ADHD

 
• By David Ridley

The studies reviewed by BMJ researchers failed to account for the fact that the association between in utero exposure to paracetamol and autism and ADHD in childhood “might be driven by familial genetic and environmental factors.”